Half of the FDA’s upcoming 2024 user fee goals target rare diseases, but highly prevalent conditions like uncomplicated urinary tract infections and atopic dermatitis are also up for agency action in the second half of the year.

AI specialist METiS Pharmaceuticals raked in $100m in a series C round, while four other deals backed by venture capital and private equity firms crossed the CNY100m ($14m) mark in the latest fundraisings by Chinese biopharma companies.

The French drugmaker can now boast seven approvals for its huge-earning IL-4/IL-13 inhibitor.

The respiratory specialist is set to hit the ground running with Ohtuvayre, the first COPD inhaled product with a novel mechanism of action to be approved in over two decades.